By Maryam Cockar
GlaxoSmithKline said Thursday that its subsidiary, ViiV Healthcare Ltd, has reported positive phase 3 studies for the dolutegravir and lamivudine drugs, demonstrating the ability to control HIV with a two-drug regimen.
GSK said that the GEMINI 1 and 2 studies demonstrated a similar efficacy of a two-drug regimen compared with the standard three-drug regimen in patients that have never undergone treatment for a specific illness.
"The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination. They affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more. Importantly, the studies show that this two-drug regimen could be an option for treatment naive patients and can support a broad range of patients living with HIV around the world," said John Pottage, chief scientific and medical officer of ViiV Healthcare.
GSK said the GEMINI studies are part of ViiV Healthcare's clinical-trial program "for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment".
Specialist HIV company ViiV Healthcare is majority owned by GSK, with Pfizer and Shionogi & Co. (4507.TO).
Write to Maryam Cockar at firstname.lastname@example.org